Hiperuricemia en pacientes con enfermedad renal crónica: ¿cuándo y con qué tratar?
Saved in:
| Title: | Hiperuricemia en pacientes con enfermedad renal crónica: ¿cuándo y con qué tratar? |
|---|---|
| Alternate Title: | Hyperuricemia in patients with chronic kidney disease: When and what to treat? |
| Authors: | Goicoechea, Marian1,2,3 marian.goicoechea@gmail.com, García-Marina, Rodrigo1 |
| Source: | Nefrologia. Jun/Jul2025, Vol. 45 Issue 6, p1-9. 9p. |
| Subjects: | CHRONIC kidney failure, CHRONICALLY ill, CARDIOVASCULAR diseases, ASYMPTOMATIC patients, KIDNEY diseases |
| Abstract (English): | Hyperuricemia is frequently associated with gout, renal disease, arterial hypertension and high cardiovascular disease. All chronic kidney disease patients with a first episode of gout should be treated with hypouricemic drugs to achieve baseline uric acid levels of less than 6 mg/dl (<5 mg/dl if tophi are present). The hypouricemic drugs of choice in patients with chronic kidney disease are allopurinol and febuxostat, always starting treatment with low doses that can be progressively increased according to tolerance. Asymptomatic hyperuricemia increases the risk of arterial hypertension, cardiovascular disease and renal disease, but at present published clinical trials do not support the treatment of asymptomatic hyperuricemia in patients with chronic kidney disease. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | La hiperuricemia se asocia frecuentemente con gota, enfermedad renal, hipertensión arterial y enfermedad cardiovascular. Todos los pacientes con enfermedad renal crónica que presentan un primer episodio de gota deben ser tratados con fármacos hipouricemiantes para conseguir un nivel basal de ácido úrico menor de 6 mg/dl (<5 mg/dl si presentan tofos). Los fármacos hipouricemiantes de elección en pacientes con enfermedad renal crónica son el alopurinol y el febuxostat. El tratamiento se inicia siempre con dosis bajas, que pueden ir aumentándose progresivamente según la tolerancia. La hiperuricemia asintomática aumenta el riesgo de hipertensión arterial, enfermedad cardiovascular y enfermedad renal, pero, en la actualidad, los ensayos clínicos publicados no avalan el tratamiento en pacientes con enfermedad renal crónica. [ABSTRACT FROM AUTHOR] |
| Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 186609933 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Hiperuricemia en pacientes con enfermedad renal crónica: ¿cuándo y con qué tratar? – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Hyperuricemia in patients with chronic kidney disease: When and what to treat? – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Goicoechea%2C+Marian%22">Goicoechea, Marian</searchLink><relatesTo>1,2,3</relatesTo><i> marian.goicoechea@gmail.com</i><br /><searchLink fieldCode="AR" term="%22García-Marina%2C+Rodrigo%22">García-Marina, Rodrigo</searchLink><relatesTo>1</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Nefrologia%22">Nefrologia</searchLink>. Jun/Jul2025, Vol. 45 Issue 6, p1-9. 9p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22CHRONIC+kidney+failure%22">CHRONIC kidney failure</searchLink><br /><searchLink fieldCode="DE" term="%22CHRONICALLY+ill%22">CHRONICALLY ill</searchLink><br /><searchLink fieldCode="DE" term="%22CARDIOVASCULAR+diseases%22">CARDIOVASCULAR diseases</searchLink><br /><searchLink fieldCode="DE" term="%22ASYMPTOMATIC+patients%22">ASYMPTOMATIC patients</searchLink><br /><searchLink fieldCode="DE" term="%22KIDNEY+diseases%22">KIDNEY diseases</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Hyperuricemia is frequently associated with gout, renal disease, arterial hypertension and high cardiovascular disease. All chronic kidney disease patients with a first episode of gout should be treated with hypouricemic drugs to achieve baseline uric acid levels of less than 6 mg/dl (<5 mg/dl if tophi are present). The hypouricemic drugs of choice in patients with chronic kidney disease are allopurinol and febuxostat, always starting treatment with low doses that can be progressively increased according to tolerance. Asymptomatic hyperuricemia increases the risk of arterial hypertension, cardiovascular disease and renal disease, but at present published clinical trials do not support the treatment of asymptomatic hyperuricemia in patients with chronic kidney disease. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: La hiperuricemia se asocia frecuentemente con gota, enfermedad renal, hipertensión arterial y enfermedad cardiovascular. Todos los pacientes con enfermedad renal crónica que presentan un primer episodio de gota deben ser tratados con fármacos hipouricemiantes para conseguir un nivel basal de ácido úrico menor de 6 mg/dl (<5 mg/dl si presentan tofos). Los fármacos hipouricemiantes de elección en pacientes con enfermedad renal crónica son el alopurinol y el febuxostat. El tratamiento se inicia siempre con dosis bajas, que pueden ir aumentándose progresivamente según la tolerancia. La hiperuricemia asintomática aumenta el riesgo de hipertensión arterial, enfermedad cardiovascular y enfermedad renal, pero, en la actualidad, los ensayos clínicos publicados no avalan el tratamiento en pacientes con enfermedad renal crónica. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=186609933 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.nefro.2025.501334 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 9 StartPage: 1 Subjects: – SubjectFull: CHRONIC kidney failure Type: general – SubjectFull: CHRONICALLY ill Type: general – SubjectFull: CARDIOVASCULAR diseases Type: general – SubjectFull: ASYMPTOMATIC patients Type: general – SubjectFull: KIDNEY diseases Type: general Titles: – TitleFull: Hiperuricemia en pacientes con enfermedad renal crónica: ¿cuándo y con qué tratar? Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Goicoechea, Marian – PersonEntity: Name: NameFull: García-Marina, Rodrigo IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: Jun/Jul2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 02116995 Numbering: – Type: volume Value: 45 – Type: issue Value: 6 Titles: – TitleFull: Nefrologia Type: main |
| ResultId | 1 |
